Abstract:
The present invention relates to pharmaceutical compositions containing a solid dispersion of N-[2,4-Bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide including formulations of the solid dispersions into powders, granules and mini-tablets, methods for manufacturing and processing the powders, granules and mini-tablets, and methods for treating cystic fibrosis employing the pharmaceutical composition.
Abstract:
The present disclosure is directed to disclosed compounds that modulate e.g., address underlying defects in cellular processing of CFTR activity.
Abstract:
The present invention provides a compound useful as a synthetic intermediate for an anti-HIV agent having an integrase inhibitory activity, and a production method thereof, and a production method of an anti-HIV agent using the synthetic intermediate. Specifically, for example, a compound represented by the formula (2′): wherein R is a fluorine atom or a methoxy group, and R400 is a hydrogen atom or a C1-C4 alkyl group, or a salt thereof, and a production method thereof, and a production method of an anti-HIV agent using the synthetic intermediate.
Abstract:
This application provides for a method of treating a subject suffering from Crohn's disease, the method comprising periodically administering to the subject an amount of laquinimod or pharmaceutically acceptable salt thereof effective to treat the subject. This application provides for use of laquinimod in the manufacture of a medicament for treating a subject suffering from Crohn's disease. This application also provides for a pharmaceutical composition comprising laquinimod for use in treating a subject suffering from Crohn's disease.
Abstract:
The present invention relates to heterocyclic substituted quinoline derivatives as allosteric inhibitors of the glycogen synthase kinase-3 (GSK-3) enzyme. Therefore, these compounds are useful for the manufacturing of a medicament designed for the treatment and/or prevention of diseases wherein GSK-3 is involved, such as neurodegenerative diseases, inflammatory diseases, cancer, diabetes, and to promote various regenerative processes.
Abstract:
The present invention relates to solid state forms of N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide (Compound 1), pharmaceutical compositions thereof and methods therewith.
Abstract:
The present invention relates to heterocyclic substituted quinoline derivatives as allosteric inhibitors of the glycogen synthase kinase-3 (GSK-3) enzyme. Therefore, these compounds are useful for the manufacturing of a medicament designed for the treatment and/or prevention of diseases wherein GSK-3 is involved, such as neurodegenerative diseases, inflammatory diseases, cancer, diabetes, and to promote various regenerative processes.
Abstract:
This invention relates to compounds of Formula I: and pharmaceutically acceptable salts thereof. This invention also provides compositions comprising a compound of this invention and the use of such compositions in methods of treating diseases and conditions that are beneficially treated by administering a CFTR potentiator.
Abstract:
The invention provides a process for the preparation of a compound of Formula 1, comprising coupling a carboxylic acid of Formula 2 with an aniline of Formula 3 in the presence of a coupling agent.
Abstract:
The present invention provides a compound of formula I, a tautomer thereof, or a pharmaceutically acceptable salt or N-oxide thereof for use in the treatment or prevention of cardiovascular disease or of an inflammatory disease or condition: wherein: V is N or CR3; X is N or CR4; Y is N or CR5; Z is N or CR6; B is —(C═O)R1, a 5- to 10-membered heteroaryl group, or a group -L′″-NRR′, wherein R and R′ are the same or different and each represents a hydrogen atom, a C1-C6 alkyl group or a C1-C6 haloalkyl group; R1 is a 5- to 10-membered heterocyclyl group, or —OR′, wherein R′ is a hydrogen atom, a C1-C6 alkyl group or a C1-C6 haloalkyl group, or R1 is a proteinogenic α amino acid, which is linked to the carbonyl moiety in the compound of formula (I) via the α amino group, which amino acid is optionally esterified at the α carboxylic acid group with a C1-C6 alkyl group or a C6-C10 aryl group, or R1 is —NR″R′″, —NRIV-L′″-CONR″R′″, or —NRIV-L′″-COOR, wherein R, R″, R′″ and RIV are the same or different and each represents a hydrogen atom, a C1-C6 alkyl group or a C1-C6 haloalkyl group; either (a) W is N and R9 and R2 together form a bond, or (b) W is CR8, R8 and R9 together form a bond and R2 is a hydrogen atom, or a C1-C6 alkyl, C1-C6 haloalkyl, C6-C10 aryl, 5- to 10-membered heteroaryl, 5- to 10-membered heterocyclyl, -L′-A2, C3-C10 cycloalkyl, or —COOR′ group, wherein R′ is a hydrogen atom or C1-C6 alkyl group, or, when Z is a moiety CR6, R2 may form, together with R6 and the carbon and nitrogen atoms which connect R2 and R6 in the formula (I), a 5- to 6-membered heterocyclic ring; R3 is a hydrogen atom, a halogen atom, or a hydroxy, C1-C6 alkyl, C1-C6 alkoxy, C1-C6 haloalkyl, C1-C6 haloalkoxy, nitro, or —NR′R″ group, wherein R′ and R″ are the same or different and each represent a hydrogen atom or C1-C6 alkyl group; R4 and R5 are the same or different and each represent a hydrogen atom, a halogen atom, or a hydroxyl, C1-C8 alkyl, C1-C8 haloalkyl, C1-C6 alkoxy, C1-C6 haloalkoxy, nitro, —NR′R″, —CO2R′″, C6-C10 aryl, 5- to 10-membered heteroaryl, 5 to 10-membered heterocyclyl, or —CO—(C1-C6 alkyl) group, wherein R′, R″ and R′″ are the same or different and each represent a hydrogen atom or C1-C6 alkyl group, or R4 and R5 and the carbon atoms bonded to R4 and R5 together form a 5- to 6-membered heterocyclic ring; R6 is a hydrogen atom, a halogen atom, or a C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkoxy, C1-C6 haloalkoxy or —CO2R′ group, wherein R′ is hydrogen or C1-C6 alkyl, or, when W is a moiety CR8, R6 may form, together with R2 and the carbon and nitrogen atoms which connect R6 and R2 in the formula (I), a 5- to 6-membered heterocyclic ring; R7 is a hydrogen atom, a halogen atom, or a C1-C6 alkyl, or C1-C6 haloalkyl group, A2 represents a C6-C10 aryl or 5- to 10-membered heteroaryl group; L′, and L′″ are the same or different and each represent a C1-C6 alkylene, C2-C6 alkenylene, or C2-C6 alkynylene group; said aryl, heteroaryl, cycloalkyl and heterocyclyl groups being unsubstituted or substituted with one or more substituents selected from halogen, hydroxy, C1-C4 alkyl, C1-C4 hydroxyalkyl, C1-C4 alkoxy, C1-C4 haloalkyl, C1-C4 haloalkoxy, —SOR, —SO2R, —NR′R″, —NR′(C═O)R″, —COOR, nitro and cyano substituents, wherein R, R′ and R″ are the same or different and each represents a hydrogen atom or C1-C4 alkyl group.